Expert Interview
A Second Opinion: Looking at the FDA approval of the Eversense 365 implantable Continuous Glucose Monitor from Senseonics
Ticker(s): SENS, ABT, DXCM, MDTInstitution: Endocrinology Associates
- Physician and CEO of Endocrinology Associates Inc, and Fellow of the American Association of Clinical Endocrinologists.
- Has published widely on an array of topics including acromegaly, diabetes, obesity, and thyroid diseases.
- Head of Endocrinology Research Associates, an independent research facility, which consults with companies in the endocrine and metabolic space
Please describe your background and patient setting
Added By: ben_adminHow many patients do you manage who utilize a CGM device?
Added By: ben_adminWhat are the most popular CGM devices used today?
Added By: ben_adminWhat is your opinion of the Eversense 365 CGM?
Added By: ben_adminHow likely are you to prescribe the Eversense CGM ?
Added By: ben_adminCan you provide an overview of the different CGMs available on the market for patients? What are the differences between these CGMs, and what do you attribute the popularity of Dexcom and FreeStyle Libre to compared to others like Eversense?
How involved is the procedure to place the implantable Eversense CGM? Is it a minor procedure, and are there specific risks or barriers, such as infection or patient preference? Does it integrate with popular pumps, and how does the accuracy of the implantable CGM compare to others?
How does insurance coverage impact CGM selection for patients? Is the cost of Eversense comparable to other CGMs, and do you expect to increase your use of Eversense in the future given its features and support?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
